Actionable Stock Market Trading Newswire. Built for Traders, by Traders.
All news is property of their respective owners.

Wedbush Maintains Outperform on Codiak BioSciences, Lowers Price Target to $24

Wedbush analyst David Nierengarten maintains Codiak BioSciences (NASDAQ:CDAK) with a Outperform and lowers the price target from $34 to $24.
byBenzinga Newsdesk
February 22, 2022
1 minute read
Total
0
Shares
0
0
0
0
0
0

Wedbush analyst David Nierengarten maintains Codiak BioSciences (NASDAQ:CDAK) with a Outperform and lowers the price target from $34 to $24.

 
Total
0
Shares
Share 0
Tweet 0
Share 0
Share 0
Share 0
Share 0